-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $23

Benzinga·07/15/2026 15:47:38
Listen to the news
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $19 to $23.